Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome

62Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: We report a 7-year-old boy with high-degree steroid-dependent idiopathic nephrotic syndrome (SDNS) who went into remission with rituximab (RTX) maintenance therapy. Case-Diagnosis/Treatment: Four months after this patient received his first RTX infusion, there was a progressive and sustained decrease of immunoglobulin (Ig)G and IgM levels. Thirteen months after the initiation of RTX therapy he was in sustained remission without any steroid or oral immunosuppressive therapy; however, B cell depletion was still present. At this time he developed a fulminant myocarditis due to enterovirus. Despite aggressive treatment and the administration of intravenous polyvalent immunoglobulins there was no clinical improvement. He successfully underwent heart transplant surgery. Conclusions: We conclude that B cell depletion with RTX is efficacious in the treatment of paediatric SDNS but that it may be associated with severe infectious complications. Therefore, we recommend a close monitoring of Ig levels in children who have received RTX therapy and a supplementation with intravenous Ig as soon as the Ig levels fall below the lower limit of the normal range © 2013 IPNA.

Cite

CITATION STYLE

APA

Sellier-Leclerc, A. L., Belli, E., Guérin, V., Dorfmüller, P., & Deschênes, G. (2013). Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatric Nephrology, 28(9), 1875–1879. https://doi.org/10.1007/s00467-013-2485-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free